259 related articles for article (PubMed ID: 24621109)
1. Extrafine beclomethasone/formoterol compared to fluticasone/salmeterol combination therapy in COPD.
Singh D; Nicolini G; Bindi E; Corradi M; Guastalla D; Kampschulte J; Pierzchała W; Sayiner A; Szilasi M; Terzano C; Vestbo J;
BMC Pulm Med; 2014 Mar; 14():43. PubMed ID: 24621109
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of single-inhaler extrafine triple therapy versus inhaled corticosteroid plus long-acting beta2 agonist in eastern Asian patients with COPD: the TRIVERSYTI randomised controlled trial.
Zheng J; Baldi S; Zhao L; Li H; Lee KH; Singh D; Papi A; Grapin F; Guasconi A; Georges G
Respir Res; 2021 Mar; 22(1):90. PubMed ID: 33757520
[TBL] [Abstract][Full Text] [Related]
3. The bronchodilator effects of extrafine glycopyrronium added to combination treatment with beclometasone dipropionate plus formoterol in COPD: A randomised crossover study (the TRIDENT study).
Singh D; Schröder-Babo W; Cohuet G; Muraro A; Bonnet-Gonod F; Petruzzelli S; Hoffmann M; Siergiejko Z;
Respir Med; 2016 May; 114():84-90. PubMed ID: 27109816
[TBL] [Abstract][Full Text] [Related]
4. Effects of beclomethasone/formoterol fixed combination on lung hyperinflation and dyspnea in COPD patients.
Tzani P; Crisafulli E; Nicolini G; Aiello M; Chetta A; Clini EM; Olivieri D
Int J Chron Obstruct Pulmon Dis; 2011; 6():503-9. PubMed ID: 22069361
[TBL] [Abstract][Full Text] [Related]
5. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial.
Papi A; Vestbo J; Fabbri L; Corradi M; Prunier H; Cohuet G; Guasconi A; Montagna I; Vezzoli S; Petruzzelli S; Scuri M; Roche N; Singh D
Lancet; 2018 Mar; 391(10125):1076-1084. PubMed ID: 29429593
[TBL] [Abstract][Full Text] [Related]
6. Fluticasone/formoterol combination therapy is as effective as fluticasone/salmeterol in the treatment of asthma, but has a more rapid onset of action: an open-label, randomized study.
Bodzenta-Lukaszyk A; Dymek A; McAulay K; Mansikka H
BMC Pulm Med; 2011 May; 11():28. PubMed ID: 21605396
[TBL] [Abstract][Full Text] [Related]
7. Acute cardiovascular safety of two formulations of beclometasone dipropionate/formoterol fumarate in COPD patients: A single-dose, randomised, placebo-controlled crossover study.
Singh D; Ciurlia G; Piccinno A; Muraro A; Bocchi M; Scuri M
Pulm Pharmacol Ther; 2017 Feb; 42():43-51. PubMed ID: 28065679
[TBL] [Abstract][Full Text] [Related]
8. Stepping-across controlled asthmatic patients to extrafine beclometasone/formoterol combination.
Barnes N; van Noord JA; Brindicci C; Lindemann L; Varoli G; Perpiña M; Guastalla D; Casula D; Patel S; Chanez P;
Pulm Pharmacol Ther; 2013 Oct; 26(5):555-61. PubMed ID: 23524015
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of aclidinium/formoterol versus salmeterol/fluticasone: a phase 3 COPD study.
Vogelmeier C; Paggiaro PL; Dorca J; Sliwinski P; Mallet M; Kirsten AM; Beier J; Seoane B; Segarra RM; Leselbaum A
Eur Respir J; 2016 Oct; 48(4):1030-1039. PubMed ID: 27492833
[TBL] [Abstract][Full Text] [Related]
10. Beclomethasone/formoterol vs fluticasone/salmeterol inhaled combination in moderate to severe asthma.
Papi A; Paggiaro P; Nicolini G; Vignola AM; Fabbri LM;
Allergy; 2007 Oct; 62(10):1182-8. PubMed ID: 17845589
[TBL] [Abstract][Full Text] [Related]
11. Comparative efficacy of indacaterol 150 μg and 300 μg versus fixed-dose combinations of formoterol + budesonide or salmeterol + fluticasone for the treatment of chronic obstructive pulmonary disease--a network meta-analysis.
Cope S; Capkun-Niggli G; Gale R; Jardim JR; Jansen JP
Int J Chron Obstruct Pulmon Dis; 2011; 6():329-44. PubMed ID: 21697997
[TBL] [Abstract][Full Text] [Related]
12. Stepping down from high dose fluticasone/salmeterol to extrafine BDP/F in asthma is cost-effective.
Paggiaro P; Patel S; Nicolini G; Pradelli L; Zaniolo O; Papi A
Respir Med; 2013 Oct; 107(10):1531-7. PubMed ID: 23916740
[TBL] [Abstract][Full Text] [Related]
13. The effect of inhaled extrafine beclometasone dipropionate/formoterol fumarate/glycopyrronium bromide on distal and central airway indices, assessed using Functional Respiratory Imaging in COPD (DARWiIN).
Skloot GS; Guasconi A; Lavon BR; Georges G; De Backer W; Galkin D; Cortellini M; Panni I; Bates JHT
Respir Res; 2023 Oct; 24(1):244. PubMed ID: 37803368
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of indacaterol 75 μg versus fixed-dose combinations of formoterol-budesonide or salmeterol-fluticasone for COPD: a network meta-analysis.
Cope S; Kraemer M; Zhang J; Capkun-Niggli G; Jansen JP
Int J Chron Obstruct Pulmon Dis; 2012; 7():415-20. PubMed ID: 22848154
[TBL] [Abstract][Full Text] [Related]
15. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial.
Singh D; Papi A; Corradi M; Pavlišová I; Montagna I; Francisco C; Cohuet G; Vezzoli S; Scuri M; Vestbo J
Lancet; 2016 Sep; 388(10048):963-73. PubMed ID: 27598678
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Dry-Powder Inhaler and Pressurized Metered-Dose Inhaler Formulations of Extrafine Beclomethasone Dipropionate/Formoterol Fumarate/Glycopyrronium in Patients with COPD: The TRI-D Randomized Controlled Trial.
Beeh KM; Kuna P; Corradi M; Viaud I; Guasconi A; Georges G
Int J Chron Obstruct Pulmon Dis; 2021; 16():79-89. PubMed ID: 33488071
[TBL] [Abstract][Full Text] [Related]
17. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial.
Vestbo J; Papi A; Corradi M; Blazhko V; Montagna I; Francisco C; Cohuet G; Vezzoli S; Scuri M; Singh D
Lancet; 2017 May; 389(10082):1919-1929. PubMed ID: 28385353
[TBL] [Abstract][Full Text] [Related]
18. Extrafine beclomethasone/formoterol in severe COPD patients with history of exacerbations.
Wedzicha JA; Singh D; Vestbo J; Paggiaro PL; Jones PW; Bonnet-Gonod F; Cohuet G; Corradi M; Vezzoli S; Petruzzelli S; Agusti A;
Respir Med; 2014 Aug; 108(8):1153-62. PubMed ID: 24953015
[TBL] [Abstract][Full Text] [Related]
19. Step-down therapy with low-dose fluticasone-salmeterol combination or medium-dose hydrofluoroalkane 134a-beclomethasone alone.
Fowler SJ; Currie GP; Lipworth BJ
J Allergy Clin Immunol; 2002 Jun; 109(6):929-35. PubMed ID: 12063520
[TBL] [Abstract][Full Text] [Related]
20. A comparison of the efficacy and safety of once-daily fluticasone furoate/vilanterol with twice-daily fluticasone propionate/salmeterol in moderate to very severe COPD.
Agustí A; de Teresa L; De Backer W; Zvarich MT; Locantore N; Barnes N; Bourbeau J; Crim C
Eur Respir J; 2014 Mar; 43(3):763-72. PubMed ID: 24114969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
